Santhera Partners with Ikris Pharma Network to Distribute AGAMREE in India

Santhera Pharmaceuticals has entered into an exclusive agreement with Ikris Pharma Network to distribute AGAMREE (vamorolone) in India. The drug is approved for treating Duchenne muscular dystrophy (DMD) in patients aged four years and older.

The five-year deal will see Santhera receive a percentage of net sales, with product availability expected to begin in the fourth quarter of 2025 on a named patient basis.

This partnership follows Santhera’s recent distribution agreements in Turkey and several Gulf Cooperation Council countries, reflecting the company’s ongoing efforts to expand global access to AGAMREE.

Santhera CEO Dario Eklund emphasized the significance of partnering with Ikris Pharma Network, citing their experience and commitment to rare disease treatments as key factors in reaching more DMD patients in India.

Ikris Pharma Network Founder and CEO Praveen Sikri expressed enthusiasm about the collaboration, highlighting their focus on addressing unmet needs in the rare disease community and improving patient access to innovative therapies.

The agreement marks another important step in Santhera’s global rollout of AGAMREE, aimed at improving outcomes for patients living with DMD.